BioMed Alliance replied to the public consultation on the HTA Implementing Regulation on joint clinical assessments of medicinal products. In the reply, BioMed Alliance argues that the involvement of stakeholders including clinicians is key to achieve a high scientific quality of joint clinical assessment reports. In order to facilitate the process and ensure the right experts are able to provide a meaningful contribution, it is necessary to ensure a systematic and consistent involvement of stakeholders, facilitate cooperation with medical societies as key partners, give sufficient time for stakeholders to provide their input, and set up appropriate conflict of interest policies. The reply is available here and on the ‘have your say’ website.